Human/Mouse VEGF-B167/186 Antibody
Human/Mouse VEGF-B167/186 Antibody Summary
Pro22-Arg188
Accession # AAB06274
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data
View Larger
VEGF‑B167/186in Human Breast Cancer Tissue. VEGF-B167/186was detected in immersion fixed paraffin-embedded sections of human breast cancer tissue using Mouse Anti-Human/Mouse VEGF-B167/186Monoclonal Antibody (Catalog # MAB751) at 3 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Mouse HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS002) and counterstained with hematoxylin (blue). Specific staining was localized to cytoplasm and cell membranes of cancer cells. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: VEGF-B
Vascular endothelial growth factor B (VEGF-B), also known as vascular endothelial growth factor-related factor (VRF), is a member of the VEGF family of growth factors that share structural and functional similarity (1, 2). Five mammalian members, including VEGF-A, -B, -C, -D and PlGF, have been identified. VEGF family members are disulfide-linked dimeric proteins that are important regulators of physiological and pathological vasculogenesis, angiogenesis and lymphangiogenesis. VEGF-B is expressed in most tissues, especially in heart, skeletal muscle and pancreas. In many tissues, VEGF-B is co-expressed and can heterodimerize with VEGF (3). By alternative splicing, two isoforms of mature VEGF-B containing 167 or 186 amino acid (aa) exist (3, 4). The two VEGF-B isoforms have identical amino-terminal cysteine-knot VEGF homology domains but the carboxyl end of VEGF-B167 differs from that of VEGF-B186 by the presence of a highly basic cysteine-rich heparin binding domain. Whereas VEGF-B186 is a secreted diffusible protein, VEGF-B167 is sequestered into the cell matrix after secretion. Both VEGF-B isoforms bind VEGF receptor 1 (VEGF R1), but not VEGF R2 or VEGF R3 (5). On endothelial cells, ligation of VEGF R1 by VEGF-B has been shown to regulate the expression and activity of urokinase type plasminogen activator and plasminogen activator inhibitor 1. VEGF-B167 and a proteolytically processed form of VEGF-B186 (VEGF-B127) also bind neuropilin-1 (NP-1), a type I transmembrane receptor for semaphorins/collapsins, ligands involved in neuron guidance (6). Besides VEGF-B, NP-1 has been shown to bind PLGF-2, VEGF165 and VEGF R1 (6, 7). The many interactions of NP-1 with VEGF ligands and receptor suggests that NP-1 may function as a regulator of angiogenesis (7).
- Li, X. and U. Eriksson (2001) Int. J. Biochem Cell Biol. 33:421.
- Olofsson, B. et al. (1999) Curr. Opin. Biotechnol. 10:528.
- Olofsson, B. et al. (1996) Proc. Nat. Acad. Sci. USA 93:2576.
- Grimmond, S. et al. (1996) Benome Res. 6:124.
- Olofsson, B. et al. (1998) Proc. Nat. Acad. Sci. USA 95:11709.
- Makinen, T. et al. (1999) J. Biol. Chem. 274:21217.
- Fuh, G. et al. (2000) J. Biol. Chem. 275:26690.
Product Datasheets
Citations for Human/Mouse VEGF-B167/186 Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
6
Citations: Showing 1 - 6
Filter your results:
Filter by:
-
FLT1 kinase is a mediator of radioresistance and survival in head and neck squamous cell carcinoma
Authors: Evert Jan Van Limbergen, Piotr Zabrocki, Michaël Porcu, Esther Hauben, Jan Cools, Sandra Nuyts
Acta Oncologica
-
Development of a method to identify persistent and blanchable redness by skin blotting in mice
Authors: Ayano Nakai, Takeo Minematsu, Shiori Nitta, Wei‐Jhen Hsu, Hiromi Tobe, Hiromi Sanada
International Wound Journal
-
An Anti-VEGF-B Antibody Reduces Abnormal Tumor Vasculature and Enhances the Effects of Chemotherapy
Authors: Janes, PW;Parslow, AC;Cao, D;Rigopoulos, A;Lee, FT;Gong, SJ;Cartwright, GA;Burvenich, IJG;Eriksson, U;Johns, TG;Scott, FE;Scott, AM;
Cancers
Species: Human
Sample Types: Whole Cells, Whole Tissue
Applications: Flow Cytometry, Immunohistochemistry -
miR-379 mediates insulin resistance and obesity through impaired angiogenesis and adipogenesis regulated by ER stress
Authors: Abdollahi M, Kato M, Lanting L et al.
Molecular Therapy - Nucleic Acids
-
Correlation of Vascular Endothelial Growth Factor subtypes and their receptors with melanoma progression: A next-generation Tissue Microarray (ngTMA) automated analysis
Authors: SM Seyed Jafa, C Wiedmer, S Cazzaniga, Ž Frangež, M Shafighi, H Beltramine, B Weber, HU Simon, RE Hunger
PLoS ONE, 2018-11-08;13(11):e0207019.
Species: Human
Sample Types: Tissue Microarray
Applications: IHC-P -
miR-379 mediates insulin resistance and obesity through impaired angiogenesis and adipogenesis regulated by ER stress
Authors: Abdollahi M, Kato M, Lanting L et al.
Molecular Therapy - Nucleic Acids
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human/Mouse VEGF-B167/186 Antibody
There are currently no reviews for this product. Be the first to review Human/Mouse VEGF-B167/186 Antibody and earn rewards!
Have you used Human/Mouse VEGF-B167/186 Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
